GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar
    Wiley ; 2016
    In:  Catheterization and Cardiovascular Interventions Vol. 88, No. 2 ( 2016-08), p. 163-173
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 88, No. 2 ( 2016-08), p. 163-173
    Abstract: We evaluated outcomes associated with transradial vs. transfemoral approaches and vorapaxar in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in the TRACER trial. Background Vorapaxar reduces ischemic events but increases the risk of major bleeding. Methods We compared 30‐day and 2‐year major adverse cardiac events (MACE: cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization) and noncoronary artery bypass graft (CABG)‐related bleedings in 2,192 transradial and 4,880 transfemoral patients undergoing PCI after adjusting for confounding variables, including propensity for transradial access. Results Overall, 30‐day GUSTO moderate/severe and non‐CABG TIMI major/minor bleeding occurred less frequently in transradial (0.9% vs. 2.0%, P  = 0.001) vs. transfemoral (1.1% vs. 2.5%, P  = 0.005) patients. A similar reduction was seen at 2 years (3.3% vs. 4.7%, P  = 0.008; 3.3% vs. 4.9%, P   〈  0.001, respectively). Transradial was associated with an increased risk of ischemic events at 30 days (OR 1.38, 95% CI 1.11–1.72; P  = 0.004), driven primarily by increased periprocedural myocardial infarctions. At 2 years, rates of MACE were comparable (HR 1.14, 95% CI 0.98–1.33; P  = 0.096). Although bleeding rates were higher with vorapaxar in transfemoral vs. transradial patients, there was no significant treatment interaction. Also, the access site did not modulate the association between vorapaxar and MACE. Conclusions Transradial access was associated with lower bleeding rates and similar long‐term ischemic outcomes, suggesting transradial access is safer than transfemoral access among ACS patients receiving potent antiplatelet therapies. Because of the nonrandomized allocation of arterial access, these results should be considered exploratory. © 2015 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v88.2
    DOI: 10.1002/ccd.26335
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Feasibility of simultaneous bilateral carotid artery stenting
    Wiley ; 2004
    In:  Catheterization and Cardiovascular Interventions Vol. 61, No. 4 ( 2004-04), p. 437-442
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 61, No. 4 ( 2004-04), p. 437-442
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Journal
    URL: Article
    DOI: 10.1002/ccd.v61:4
    DOI: 10.1002/(ISSN)1522-726X
    DOI: 10.1002/ccd.10742
    Language: English
    Publisher: Wiley
    Publication Date: 2004
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Contemporary practice pattern of permanent pacing for conduction disorders in inferior ST‐elevation myocardial infarction
    Wiley ; 2019
    In:  Clinical Cardiology Vol. 42, No. 8 ( 2019-08), p. 728-734
    Details
    In: Clinical Cardiology, Wiley, Vol. 42, No. 8 ( 2019-08), p. 728-734
    Abstract: Currently, there is no clear consensus regarding the optimal waiting period before permanent pacemaker implantation in patients with conduction disorders following an inferior myocardial infarction. Hypothesis We aimed to elucidate the contemporary practice pattern of pacing, especially the timing of pacemaker implantation, for sinoatrial node and atrioventricular (AV) conduction disorders following an inferior ST‐elevation myocardial infarction (STEMI). Methods Using the National Inpatient Sample database from 2010 to 2014, we identified patients with a primary diagnosis of inferior STEMI. Primary conduction disorders were classified into: (a) high‐degree AV block (HDAVB) consisting of complete AV block or Mobitz‐type II second‐degree AV block, (b) sinoatrial node dysfunction (SND), and (c) no major conduction disorders. Results Among 66 961 patients, 2706 patients (4.0%) had HDAVB, which mostly consisted of complete AV block (2594 patients). SND was observed in 393 patients (0.6%). Among the 2706 patients with HDAVB, 267 patients (9.9%) underwent permanent pacemaker. In patients with HDAVB, more than one‐third (34.9%) of permanent pacemakers were placed within 72 hours after admission. The median interval from admission to permanent pacemaker implantation was 3 days (interquartile range; 2‐5 days) for HDAVB vs 4 days (3‐6 days) for SND ( P   〈  .001). HDAVB was associated with increased in‐hospital mortality, whereas SND was not. Conclusions In patients who developed HDAVB following an inferior STEMI, only one in 10 patients underwent permanent pacemaker implantation. Despite its highly reversible nature, permanent pacemakers were implanted relatively early.
    Type of Medium: Online Resource
    ISSN: 0160-9289 , 1932-8737
    URL: Issue
    URL: Article
    DOI: 10.1002/clc.v42.8
    DOI: 10.1002/clc.23210
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2048223-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Efficacy and safety of short‐term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta‐analysis of randomized controlled trials
    Wiley ; 2018
    In:  Clinical Cardiology Vol. 41, No. 11 ( 2018-11), p. 1455-1462
    Details
    In: Clinical Cardiology, Wiley, Vol. 41, No. 11 ( 2018-11), p. 1455-1462
    Abstract: Patients who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are at increased risk for subsequent ischemic events. Hypothesis Short‐term dual antiplatelet therapy (DAPT) (≤6 months) is inferior to standard or long‐term DAPT in patients who undergo PCI for ACS events. Methods We conducted a systematic review and meta‐analysis of randomized controlled trials that compared short‐term (≤6 months) to long‐term (≥12 months) DAPT after PCI for ACS. We searched MEDLINE, EMBASE, SCOPUS, and the Cochrane Central Register of Controlled Trials database. Results Ten randomized controlled trials, including a total of 12 696 patients, met our inclusion criteria. For short‐term DAPT, duration of therapy ranged from 3 to 6 months, while long‐term DAPT ranged from 12 to 24 months. The majority of studies used clopidogrel and second‐generation drug‐eluting stents. No statistically significant difference was found between short‐term and long‐term DAPT with regard to myocardial infarction (odds ratio 1.21; 95% confidence interval 0.94‐1.57; P  = 0.14), stent thrombosis (odds ratio 1.54; 95% confidence interval 1.00‐2.38; P  = 0.052), or major bleeding events (odds ratio 0.74; 95% confidence interval 0.49‐1.11; P  = 0.14). There was no significant difference in all‐cause mortality, cardiac death, or net adverse cardiac and cerebrovascular events. Conclusions Our meta‐analysis demonstrated that short‐term DAPT ( 〈 6 months) after PCI for ACS was not associated with increased risk of myocardial infarction or stent thrombosis when compared to long‐term DAPT.
    Type of Medium: Online Resource
    ISSN: 0160-9289 , 1932-8737
    URL: Issue
    URL: Article
    DOI: 10.1002/clc.2018.41.issue-11
    DOI: 10.1002/clc.23075
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2048223-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Delayed Lead Perforation: A Disturbing Trend
    Wiley ; 2005
    In:  Pacing and Clinical Electrophysiology Vol. 28, No. 3 ( 2005-03), p. 251-253
    Details
    In: Pacing and Clinical Electrophysiology, Wiley, Vol. 28, No. 3 ( 2005-03), p. 251-253
    Abstract: Background: Delayed lead perforation (occurring more than 1 month after implantation) is a rare complication. Its pathophysiology and optimal management are currently unclear. Methods: Three cases of delayed lead perforation (6–10 month) were identified in patients with low‐profile active fixation leads. Results: All cases presented in a subacute fashion with pleuritic chest pain with confirmatory chest x‐ray and device interrogation. Given the potential complications of a perforated lead, all cases had the lead extracted under TEE observation with cardiac surgery backup in the operating room. All patients tolerated extraction without complication. Conclusion: Based on these cases, we recommend a management scheme for patients who present with delayed lead perforation.
    Type of Medium: Online Resource
    ISSN: 0147-8389 , 1540-8159
    URL: Issue
    URL: Article
    DOI: 10.1111/pace.2005.28.issue-3
    DOI: 10.1111/j.1540-8159.2005.40003.x
    Language: English
    Publisher: Wiley
    Publication Date: 2005
    detail.hit.zdb_id: 2037547-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Incidence, nature, and temporal trends of adverse events associated with noncardiac procedures among veterans with drug‐eluting coronary artery stents
    Wiley ; 2015
    In:  Catheterization and Cardiovascular Interventions Vol. 86, No. 2 ( 2015-08), p. 211-219
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 86, No. 2 ( 2015-08), p. 211-219
    Abstract: Background: The incidence of adverse events with noncardiac procedures (NCP) after the use of drug eluting stents (DES) is not well studied. We sought to determine the incidence and temporal trends of adverse events in patients undergoing NCP after coronary DES. Methods: We performed a retrospective review of patients receiving DES during percutaneous coronary intervention (PCI) in the Lexington VAMC between January 1, 2004 and December 31, 2010 to determine the circumstances and the results of their NCP. Results: We identified 1,092 patients who underwent at least one PCI with DES who were followed for at least 3 years. Of those, 452 patients (41%) had a NCP at a median of 534 days after PCI with 1,081 procedures (894 low‐, 160 Intermediate‐, and 27 high‐risk) performed. Clinically relevant NCP‐related complications were defined as significant bleeding or stent thrombosis and occurred in 13 individuals (nine perioperative bleeding and four probable/possible stent thrombosis including two mortalities). Five adverse events occurred within the first year at a rate of 0.014 event/patient‐year. During the remainder of follow‐up (up to 9 years), eight events were documented at a rate of 0.0004 event/patient‐years. During the first year of follow‐up, there was no significant increase in risk of recurrent myocardial infarction (MI) or target vessel revascularization (TVR) in patients undergoing NCP but higher risk of all‐cause mortality in those who did not undergo NCP. However, in patients who underwent NCP, there was a statistically significant increase in myocardial infarction (MI), target vessel revascularization (TVR), and rehospitalization for cardiac reasons compared with those without NCP during long term follow‐up (median of 5.6 years). Conclusion: NCP after DES requiring management of DAT are relatively common among veterans following PCI using DES. The risk of bleeding and stent thrombosis is concentrated in the first year but remains very low. © 2015 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v86.2
    DOI: 10.1002/ccd.25706
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Feasibility of transradial primary percutaneous coronary intervention for STEMI complicated by cardiac arrest
    Wiley ; 2022
    In:  Catheterization and Cardiovascular Interventions Vol. 99, No. 4 ( 2022-03), p. 1363-1365
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 99, No. 4 ( 2022-03), p. 1363-1365
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v99.4
    DOI: 10.1002/ccd.30022
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Drug‐eluting stents in patients with end‐stage renal disease: Meta‐analysis and systematic review of the literature
    Wiley ; 2010
    In:  Catheterization and Cardiovascular Interventions Vol. 76, No. 7 ( 2010-12), p. 942-948
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 76, No. 7 ( 2010-12), p. 942-948
    Abstract: Objective : The study sought to examine the total weight of evidence regarding the use of drug eluting (DES) and bare metal stents (BMS) in patients with end stage renal disease (ESRD). Background : The potential superiority of DES over BMS in reducing target lesion or vessel revascularization (TLR or TVR) in patients with ESRD on dialysis has not been established. Small studies comparing DES to BMS in this population have yielded inconclusive results mainly due to the small sample size. Methods : We searched MEDLINE, EMBASE, Science Citation Index, CINAHL, and the Cochrane CENTRAL database of controlled clinical trials (December 2009) for controlled trials comparing DES to BMS in ESRD patients. We conducted a fixed‐effects meta‐analysis across seven eligible studies ( n = 869 patients). Results : Compared with BMS‐treated patients, DES‐treated patients had significantly lower TLR/TVR (OR 0.55 CI: 0.39–0.79) and major adverse cardiac events (MACE) (OR 0.54; CI: 0.40–0.73). The absolute risk reduction (ARR) with DES in TLR/TVR was −0.09 (CI: −0.14 to −0.04; NNT 11) and in MACE was −0.13 (CI: −0.19 to −0.07; NNT 8). A trend towards lower incidence of all cause mortality was also noted with DES (OR 0.68; CI: 0.45–1.01). No significant differences were noted between both groups in the relative or absolute risk of myocardial infarction. Conclusion : The use of DES in patients with ESRD is safe and yields significant reduction in the risk of TLR/TVR and MACE. Larger randomized studies are needed to confirm the results of this meta‐analysis and establish the appropriate stent choice in this high risk population. © 2010 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v76:7
    DOI: 10.1002/ccd.22562
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second‐generation drug‐eluting stents for coronary artery disease: A systematic review and meta‐analysis of randomized trials
    Wiley ; 2016
    In:  Catheterization and Cardiovascular Interventions Vol. 87, No. 4 ( 2016-03), p. 722-732
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 87, No. 4 ( 2016-03), p. 722-732
    Abstract: Dual antiplatelet therapy (DAPT) is recommended for ≥12 months following coronary drug‐eluting stents (DES) to reduce risk of major adverse ischemic events. Randomized trials suggest an abbreviated DAPT duration (≤6 months) is adequately protective. However, these trials are individually underpowered to detect differences in rare but serious events such as stent thrombosis (ST). Objectives We performed a meta‐analysis of published randomized trials to define the impact of abbreviated DAPT (≤6 months) on death, myocardial infarction (MI), stent thrombosis (ST), and bleeding complications compared to standard‐duration DAPT (≥12 months). Methods Seven randomized controlled trials comparing abbreviated vs. standard DAPT regimens following DES use were identified by two independent investigators. Study characteristics were reviewed and clinical endpoint data were abstracted and analyzed in aggregate using fixed and random‐effects models. Results The seven trials included 15,874 randomized patients. Second‐generation DES were used in most patients. Compared to standard‐duration DAPT, abbreviated DAPT was not associated with an increase in mortality (OR 0.93; CI: 0.73 to 1.17; P  = 0.52), MI (OR 1.14; CI: 0.89 to 1.45; P  = 0.30) or ST (OR 1.25; CI: 0.81 to 1.93; P  = 0.31). Abbreviated DAPT was associated with significantly fewer major bleeding complications (OR 0.52; CI: 0.34 to 0.82; P  = 0.005). The results were consistent between fixed and random‐effects models, with no heterogeneity. Sensitivity analyses adjusting for inclusion of bare metal stents, 1st generation DES and/or abbreviated DAPT regimens of 3 months resulted in similar conclusions. Conclusions In a meta‐analysis of 〉 15,000 patients primarily treated with second‐generation DES, abbreviated‐duration DAPT (≤6 months) was associated with a significant reduction in major bleeding complications with no evidence of a significant increase in risk of death, MI or ST. Accordingly, abbreviated DAPT should be strongly considered for patients receiving second generation DES . © 2015 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v87.4
    DOI: 10.1002/ccd.26110
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Comparison of intracoronary versus intravenous adenosine‐induced maximal hyperemia for fractional flow reserve measurement: A systematic review and meta‐analysis
    Wiley ; 2019
    In:  Catheterization and Cardiovascular Interventions Vol. 94, No. 5 ( 2019-11), p. 714-721
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 94, No. 5 ( 2019-11), p. 714-721
    Abstract: We sought to perform a systematic review and meta‐analysis of the available literature comparing fractional flow reserve (FFR) measurements after administration of adenosine using intracoronary (IC) bolus versus standard continuous intravenous (IV) infusion. Background FFR is considered the gold standard for invasive assessment of coronary lesions of intermediate severity. IV adenosine is recommended to induce hyperemia; however, IC adenosine is widely used for convenience. The difference between IV and IC administration in lesions assessment is not well studied. Methods We systematically searched MEDLINE and relevant databases for studies comparing IV with IC adenosine administration for FFR measurement. We reviewed data pertaining to adenosine doses, side effects, and FFR values. Results Eight studies addressing the primary question were identified. Dose of IC adenosine varied between 36 and 600 μg. Compared to IV adenosine infusion, the sensitivity of IC administration is 0.805 (95% confidence interval [95% CI]: 0.664–0.896; p   〈  .001), specificity is 0.965 (95% CI: 0.932–0.983; p   〈  .001), positive likelihood ratio is 24.218 (95% CI: 12,263–47.830; p   〈  .001), negative likelihood ratio is 0.117 (95% CI: 0.033–0.411; p   〈  .01), and diagnostic odds ratio is 274.225 [95% CI: 92.731–810.946; p   〈  .001]. Overall, hemodynamic side effects and symptoms were reported more frequently with IV adenosine. Conclusions The available literature suggests that IC adenosine is well tolerated and may provide equivalent diagnostic accuracy compared to IV administration. However, variability in dosing regimens does not allow definitive conclusions regarding noninferiority of IC approach compared to IV administration.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v94.5
    DOI: 10.1002/ccd.28317
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...